About the Chronic Myeloid Leukemia Session
Chronic Myeloid Leukemia (CML) stands out in cancer research due to the groundbreaking targeted therapy it has inspired. With the discovery of the BCR-ABL fusion gene as its hallmark, researchers developed tyrosine kinase inhibitors (TKIs) like imatinib, revolutionizing treatment. Despite TKIs' effectiveness, challenges persist, including drug resistance and long-term side effects. Ongoing studies explore novel therapeutic approaches, including combination therapies and immunotherapies, aiming for deeper and more durable responses. Additionally, efforts focus on identifying biomarkers for predicting treatment response and monitoring disease progression. The success story of CML research underscores the potential of precision medicine in cancer treatment, offering hope for improved outcomes and quality of life for patients.
Topics Covered in Chronic Myeloid Leukemia
BCR-ABL Oncoprotein
TKI Resistance
Deep Molecular Response
Leukemic Stem Cells
Allogeneic Transplant
Long-Term Toxicity
Related Scientific Sessions at CIOC 2027
Why Attend the Chronic Myeloid Leukemia Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Chronic Myeloid Leukemia work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Chronic Myeloid Leukemia research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Chronic Myeloid Leukemia track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Chronic Myeloid Leukemia Conference 2027 — FAQs
What is the Chronic Myeloid Leukemia track at CIOC 2027?
The Chronic Myeloid Leukemia track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Chronic Myeloid Leukemia. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Chronic Myeloid Leukemia sessions?
Cancer researchers and clinicians, educators and students with an interest in Chronic Myeloid Leukemia are all welcome — whether presenting or attending.
Can I present my research in the Chronic Myeloid Leukemia track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Chronic Myeloid Leukemia sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Chronic Myeloid Leukemia track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.